CK Life Sciences Int'l., (Holdings) Inc. (HKG:0775)
Hong Kong
· Delayed Price · Currency is HKD 0.720
-0.010 (-1.37%)
Apr 29, 2026, 4:08 PM HKT
HKG:0775 Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 5,410 | 5,523 | 5,323 | 5,276 | 5,402 | Upgrade
|
| Revenue Growth (YoY) | -2.04% | 3.76% | 0.89% | -2.35% | 9.30% | Upgrade
|
| Cost of Revenue | 3,833 | 3,830 | 3,686 | 3,650 | 3,772 | Upgrade
|
| Gross Profit | 1,577 | 1,693 | 1,637 | 1,626 | 1,630 | Upgrade
|
| Selling, General & Admin | 705.67 | 655.4 | 593.38 | 536.56 | 571.56 | Upgrade
|
| Amortization of Goodwill & Intangibles | 2.47 | 2.51 | 2.55 | 3.17 | 7.59 | Upgrade
|
| Other Operating Expenses | 916.41 | 867.98 | 723.86 | 747.93 | 707.51 | Upgrade
|
| Operating Expenses | 1,708 | 1,615 | 1,413 | 1,386 | 1,393 | Upgrade
|
| Operating Income | -131.03 | 77.46 | 223.85 | 239.92 | 236.61 | Upgrade
|
| Interest Expense | -266.89 | -337.18 | -322.43 | -163.09 | -97.82 | Upgrade
|
| Interest & Investment Income | 21.2 | 13.9 | 13.18 | 5.78 | 1.43 | Upgrade
|
| Earnings From Equity Investments | 0.36 | 0.15 | 0.33 | 0.02 | 1.21 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.29 | -4.2 | -11.52 | -3.48 | 4.21 | Upgrade
|
| Other Non Operating Income (Expenses) | 64.46 | 45.08 | 31.52 | 27.79 | 28.77 | Upgrade
|
| EBT Excluding Unusual Items | -310.61 | -204.8 | -65.06 | 106.95 | 174.4 | Upgrade
|
| Impairment of Goodwill | -147.79 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.66 | 5.4 | -0.35 | 0.52 | -1.05 | Upgrade
|
| Gain (Loss) on Sale of Assets | 693.46 | 244.83 | 94.63 | 51.51 | -0.76 | Upgrade
|
| Asset Writedown | -253.72 | -136.91 | 39.37 | 43.72 | 61.13 | Upgrade
|
| Other Unusual Items | - | - | - | 2.16 | 4.52 | Upgrade
|
| Pretax Income | -18.01 | -91.48 | 68.58 | 204.86 | 238.24 | Upgrade
|
| Income Tax Expense | 170.44 | 35.07 | 51.33 | 72.91 | 75.44 | Upgrade
|
| Earnings From Continuing Operations | -188.45 | -126.55 | 17.25 | 131.95 | 162.8 | Upgrade
|
| Minority Interest in Earnings | 1.64 | - | - | 0.01 | - | Upgrade
|
| Net Income | -186.81 | -126.55 | 17.25 | 131.96 | 162.8 | Upgrade
|
| Net Income to Common | -186.81 | -126.55 | 17.25 | 131.96 | 162.8 | Upgrade
|
| Net Income Growth | - | - | -86.93% | -18.94% | 30.00% | Upgrade
|
| Shares Outstanding (Basic) | 9,611 | 9,611 | 9,611 | 9,611 | 9,611 | Upgrade
|
| Shares Outstanding (Diluted) | 9,611 | 9,611 | 9,611 | 9,611 | 9,611 | Upgrade
|
| EPS (Basic) | -0.02 | -0.01 | 0.00 | 0.01 | 0.02 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.01 | 0.00 | 0.01 | 0.02 | Upgrade
|
| EPS Growth | - | - | -86.93% | -18.94% | 30.29% | Upgrade
|
| Free Cash Flow | -58.03 | 157.01 | 226.51 | 147.64 | 207.37 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | 0.02 | 0.02 | 0.01 | 0.02 | Upgrade
|
| Dividend Per Share | - | - | - | 0.008 | 0.010 | Upgrade
|
| Dividend Growth | - | - | - | -20.00% | - | Upgrade
|
| Gross Margin | 29.15% | 30.65% | 30.76% | 30.82% | 30.17% | Upgrade
|
| Operating Margin | -2.42% | 1.40% | 4.21% | 4.55% | 4.38% | Upgrade
|
| Profit Margin | -3.45% | -2.29% | 0.32% | 2.50% | 3.01% | Upgrade
|
| Free Cash Flow Margin | -1.07% | 2.84% | 4.25% | 2.80% | 3.84% | Upgrade
|
| EBITDA | 31.5 | 243.94 | 380.71 | 393.78 | 400.34 | Upgrade
|
| EBITDA Margin | 0.58% | 4.42% | 7.15% | 7.46% | 7.41% | Upgrade
|
| D&A For EBITDA | 162.53 | 166.47 | 156.86 | 153.86 | 163.73 | Upgrade
|
| EBIT | -131.03 | 77.46 | 223.85 | 239.92 | 236.61 | Upgrade
|
| EBIT Margin | -2.42% | 1.40% | 4.21% | 4.55% | 4.38% | Upgrade
|
| Effective Tax Rate | - | - | 74.85% | 35.59% | 31.66% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.